Pipeline

Science

Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states.

See the mechanism of action of inarigivir soproxil, our lead development candidate for the treatment of hepatitis B virus (HBV)

You are now leaving Spring Bank Pharmaceutical’s website. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Spring Bank Pharmaceutical does not endorse and/or influence the content found on websites not owned/operated by us.

You are now leaving Spring Bank Pharmaceutical’s website. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Spring Bank Pharmaceutical does not endorse and/or influence the content found on websites not owned/operated by us.